|Have Questions?||Leave a Message or Start an on-line Chat|
The CDC45 recombinant monoclonal antibody is generated using DNA recombinant technology and in vitro genetic manipulation. The process begins with the immunization of an animal using a synthesized peptide derived from human CDC45, followed by the isolation of B cells and subsequent selection of positive B cells. These selected B cells undergo screening and identification of single clones. The light and heavy chains of the CDC45 antibody are amplified through PCR and inserted into a plasmid vector to create a recombinant vector. This vector is then introduced into a host cell line for antibody expression. The CDC45 recombinant monoclonal antibody is purified from the cell culture supernatant using affinity chromatography. It specifically recognizes human CDC45 protein and is particularly useful in ELISA.
The CDC45 is a member of the conserved pre-initiation complex (pre-IC) that forms at the origin of replication and helps to initiate DNA replication. Specifically, CDC45 binds to other proteins in the pre-IC, such as MCM2-7 and GINS, to form the active CMG helicase complex, which unwinds the double-stranded DNA at the origin of replication, allowing other replication machinery to access the DNA and begin the process of copying the genetic material. CDC45 has also been implicated in other cellular processes, such as the DNA damage response and cell cycle regulation.
There are currently no reviews for this product.